Open menu

Nanotechnology Business News

The latest product and company news

RSS Subscribe to our Nanotechnology Business News feed

Abraxis Receives Approval to Market ABRAXANE for Metastatic Breast Cancer in Europe

Abraxis BioScience, Inc., an integrated biotechnology company, today announced that the European Commission has granted marketing approval for ABRAXANE powder for suspension for infusion (an albumin-bound nanoparticle formulation of paclitaxel) for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.

Posted: Jan 23rd, 2008

Read more

Nanostellar CEO to Address Members of World Economic Forum on 'Green' Job-Growth Initiatives

Nanostellar CEO Pankaj Dhingra will join a list of distinguished panelists at the World Economic Form in Davos, Switzerland, to address the entrepreneurial opportunities created by global warming. The panel, which takes place January 24, 2008, will turn its attention to the opportunities that the development and growth of 'green' initiatives can play in job creation and economic stimulation.

Posted: Jan 22nd, 2008

Read more

White Paper Examines Testing For Nanotechnology Healthcare

A new white paper examines Neutron Activation Analysis (NAA) as a means for testing contaminant levels for healthcare solutions based on nanotechnology. The white paper, posted on ElementalAnalysis.com, discusses how NAA tests exhibit accuracies up to parts per quadrillion.

Posted: Jan 22nd, 2008

Read more

Analytical NanoTechnologies To Float On AIM, Names New CEO

NanoTechnologies (U.K.), a Sedgefield-based developer and manufacturer of nanotechnology air-monitoring equipment, such as 'sniffer machines' for detecting airborne contaminates including biochemicals, biological agents and explosives, said Monday that it has appointed W H Ireland Corporate Finance as broker.

Posted: Jan 21st, 2008

Read more

Arrowhead Research Units to Combine

Nanotechnology developer Arrowhead Research Corp. said Friday its subsidiary Calando Pharmaceuticals Inc. will become part of another of its subsidiaries, Insert Therapeutics Inc.

Posted: Jan 19th, 2008

Read more